Critical evaluation of biodegradable polymers used in nanodrugs

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 3071-3091

  Marin, Edgar ^a,b,c   Briceño, Maria Isabel ^b   Caballero George, Catherina ^a  

^a Institute of Scientific Research and High Technology Services   (Panama)

^b Nano Dispersions Technology   (Panama)

^c ACHARYA NAGARJUNA UNIVERSITY   (India)

Author keywords

Biodegradable polymers; Biomedical applications; Cellular uptake; Drug delivery; Nanoparticles

Indexed keywords

2 HYDROXYACID; ALPHA AMINO ACID; ANTINEOPLASTIC AGENT; BIODEGRADABLE POLYMER; CARBOXYMETHYLCELLULOSE; CISPLATIN; CLATHRIN; CURCUMIN; CYTOSTATIC AGENT; DOCETAXEL; DRUG; NANOCARRIER; NANOPARTICLE; PACLITAXEL; POLYDEPSIPEPTIDE; POLYESTER; POLYMER; TISSUE SCAFFOLD; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; AQUEOUS SOLUTION; ARTICLE; BACTERIAL INFECTION; BIOCOMPATIBILITY; BIODEGRADABILITY; BIOMEDICINE; BLOOD BRAIN BARRIER; BLOOD VESSEL; CARDIOVASCULAR DISEASE; CARTILAGE; CAVEOLA; CELL TRANSPORT; CHEMICAL ANALYSIS; CHEMICAL REACTION; CLASSIFICATION; DEGENERATIVE DISEASE; DEGRADATION; DEHYDRATION; DIFFUSION; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG TARGETING; DRUG UPTAKE; ENCAPSULATION; ENDOCYTOSIS; ENZYME DEGRADATION; EPITHELIUM CELL; FOOD AND DRUG ADMINISTRATION; HUMAN; HYDROLYSIS; HYDROPHILICITY; INTERNALIZATION; MALIGNANT NEOPLASTIC DISEASE; MITOCHONDRION; NANOTECHNOLOGY; NONHUMAN; OSTEOPOROSIS; OXIDATION; PARASITOSIS; PARTICLE SIZE; PHYSICAL CHEMISTRY; PINOCYTOSIS; POLYMERIZATION; REPRODUCIBILITY; RING OPENING; SKIN; SUPERCRITICAL FLUID; SYNTHESIS; TRANSESTERIFICATION; VIRUS INFECTION;

BIODEGRADABLE POLYMERS; BIOMEDICAL APPLICATIONS; CELLULAR UPTAKE; DRUG DELIVERY; NANOPARTICLES;

ANIMALS; BIOCOMPATIBLE MATERIALS; CELL LINE; DRUG CARRIERS; ENDOCYTOSIS; HUMANS; MICE; NANOMEDICINE; NANOPARTICLES; POLYMERS;

EID: 84882585441     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S47186     Document Type: Article

References (178)

1. Liechty WB, Peppas NA. Expert opinion: responsive polymer nanoparticles in cancer therapy. Eur J Pharm Biopharm. 2012;80:241-246.
2. Ryvolova M, Chomoucka J, Drbohlavova J, et al. Modern micro and nanoparticle-based imaging techniques. Sensors (Basel). 2012;12: 14792-14820.
3. Ulery BD, Nair LS, Laurencin CT. Biomedical applications of biodegradable polymers. J Polym Sci B Polym Phys. 2011;49:832-864.
4. Vroman I, Tighzert L. Biodegradable polymers. Materials. 2009;2: 307-344.
5. Nitta SK, Numata K. Biopolymer-based nanoparticles for drug/gene delivery and tissue engineering. Int J Mol Sci. 2013;14:1629-1654.
6. Nair LS, Laurencin CT. Polymers as biomaterials for tissue engineering and controlled drug delivery. Adv Biochem Eng Biotechnol. 2006;102:47-90.
7. Park JH, Ye M, Park K. Biodegradable polymers for microencapsulation of drugs. Molecules. 2005;10:146-161.
8. Mohanraj V, Chen Y. Nanoparticles: a review. Trop J Pharm Res. 2006;5:561-573.
9. Elzoghby AO, Samy WM, Elgindy NA. Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release. 2012;157:168-182.
10. Malhotra M, Lane C, Tomaro-Duchesneau C, Saha S, Prakash S. A novel method for synthesizing PEGylated chitosan nanoparticles: strategy, preparation, and in vitro analysis. Int J Nanomedicine. 2011;6:485-494.
11. Bhattacharyya SS, Paul S, Khuda-Bukhsh AR. Encapsulated plant extract (Gelsemium sempervirens) poly (lactide-co-glycolide) nanoparticles enhance cellular uptake and increase bioactivity in vitro. Exp Biol Med (Maywood). 2010;235:678-688.
12. Grenha A, Grainger CI, Dailey LA, et al. Chitosan nanoparticles are compatible with respiratory epithelial cells in vitro. Eur J Pharm Sci. 2007;31:73-84.
13. Liu H, Slamovich EB, Webster TJ. Less harmful acidic degradation of poly(lacticco-glycolic acid) bone tissue engineering scaffolds through titania nanoparticle addition. Int J Nanomedicine. 2006;1:541-545.
14. Ceonzo K, Gaynor A, Shaffer L, Kojima K, Vacanti CA, Stahl GL. Polyglycolic acid-induced inflammation: role of hydrolysis and resulting complement activation. Tissue Eng. 2006;12:301-308.
15. Lyu S, Untereker D. Degradability of polymers for implantable biomedical devices. Int J Mol Sci. 2009;10:4033-4065.
16. Jain A, Gupta Y, Jain SK. Perspectives of biodegradable natural polysaccharides for site-specific drug delivery to the colon. J Pharm Pharm Sci. 2007;10:86-128.
17. Modi G, Pillay V, Choonara YE. Advances in the treatment of neurodegenerative disorders employing nanotechnology. Ann N Y Acad Sci. 2010;1184:154-172.
18. Patel DN, Bailey SR. Nanotechnology in cardiovascular medicine. Catheter Cardiovasc Interv. 2007;69:643-654.
19. Hu D, Liu L, Chen W, Li S, Zhao Y. A novel preparation method for 5-aminosalicylic acid loaded Eudragit s100 nanoparticles. Int J Mol Sci. 2012;13:6454-6468.
20. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release. 2001;70:1-20.
21. Bawa R. NanoBiotech 2008: exploring global advances in nanomedicine. Nanomedicine. 2009;5:5-7.
22. Tangpasuthadol V, Pendharkar SM, Kohn J. Hydrolytic degradation of tyrosine-derived polycarbonates, a class of new biomaterials. Part I: study of model compounds. Biomaterials. 2000;21:2371-2378.
23. Jeong SI, Kim BS, Kang SW, et al. In vivo biocompatibilty and degradation behavior of elastic poly(L-lactide-co-epsilon-caprolactone) scaffolds. Biomaterials. 2004;25:5939-5946.
24. Rawat M, Singh D, Saraf S. Nanocarriers: promising vehicle for bioactive drugs. Biol Pharm Bull. 2006;29:1790-1798.
25. Kulkarni RK, Pani KC, Neuman C, Leonard F. Polylactic acid for surgical implants. Arch Surg. 1966;93:839-843.
26. Yan H, Jiang W, Zhang Y, et al. Novel multi-biotin grafted poly(lactic acid) and its self-assembling nanoparticles capable of binding to streptavidin. Int J Nanomedicine. 2012;7:457-465.
27. Godin B, Sakamoto JH, Serda RE, Grattoni A, Bouamrani A, Ferrari M. Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases. Trends Pharmacol Sci. 2010;31:199-205.
28. Lee CH. Characterization of nitric oxide delivery systems produced by various nanotechnologies. Methods Mol Biol. 2011;704:169-185.
29. Saraiva J, Marotta-Oliveira SS, Cicillini SA, Eloy Jde O, Marchetti JM. Nanocarriers for nitric oxide delivery. J Drug Deliv. 2011;2011: 936438.
30. El-Sherbiny IM, Smyth HD. Controlled release pulmonary administration of curcumin using swellable biocompatible microparticles. Mol Pharm. 2012;9:269-280.
31. Zhang XD, Wu D, Shen X, et al. Size-dependent in vivo toxicity of PEGcoated gold nanoparticles. Int J Nanomedicine. 2011;6:2071-2081.
32. Xu X, Yu H, Gao S, Ma HQ, Leong KW, Wang S. Polyphosphoester microspheres for sustained release of biologically active nerve growth factor. Biomaterials. 2002;23:3765-3772.
33. Shenoy D, Little S, Langer R, Amiji M. Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs. 1. In vitro evaluations. Mol Pharm. 2005;2:357-366.
34. Cheng L, Jin C, Lv W, Ding Q, Han X. Developing a highly stable PLGA-mPEG nanoparticle loaded with cisplatin for chemotherapy of ovarian cancer. PLoS One. 2011;6:e25433.
35. Chuang KH, Wang HE, Chen FM, et al. Endocytosis of PEGylated agents enhances cancer imaging and anticancer efficacy. Mol Cancer Ther. 2010;9:1903-1912.
36. Mo X, Iwata H, Matsuda S, Ikada Y. Soft tissue adhesive composed of modified gelatin and polysaccharides. J Biomater Sci Polym Ed. 2000;11:341-351.
37. Ikada Y, Tsuji H. Biodegradable polyesters for medical and ecological applications. Macromol Rapid Commun. 2000;21:117-132.
38. Hino M, Ishiko O, Honda KI, et al. Transmission of symptomatic parvovirus B19 infection by fibrin sealant used during surgery. Br J Haematol. 2000;108:194-195.
39. Lu JM, Wang X, Marin-Muller C, et al. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn. 2009;9:325-341.
40. Sachlos E, Czernuszka JT. Making tissue engineering scaffolds work. Review: the application of solid freeform fabrication technology to the production of tissue engineering scaffolds. Eur Cell Mater. 2003;5:29-39.
41. Feng Y, Guo J. Biodegradable polydepsipeptides. Int J Mol Sci. 2009;10:589-615.
42. Garaleh M. Synthesis of poly(ether-ester) catalyzed by bismuth triflate. Eur J Sci Res. 2011;55:383-387.
43. Rodriguez-Galan A, Franco L, Puiggali J. Degradable poly(ester amide)s for biomedical applications. Polymers. 2011;3:69-99.
44. Stridsberg KM, Ryner M, Albertsson AC. Controlled ring-opening polymerization: polymers with designed macromolecular architecture. Degradable Aliphatic Polyesters. Berlin, Germany: Springer; 2002.
45. Merlin DL, Sivasankar B. Synthesis and characterization of semiinterpenetrating polymer networks using biocompatible polyurethane and acrylamide monomer. Eur Polym J. 2009;45:165-170.
46. Macocinschi D, Filip D, Vlad S, Oprea AM, Gafitanu CA. Characterization of a poly(ether urethane)-based controlled release membrane system for delivery of ketoprofen. Appl Surf Sci. 2012;259:416-423.
47. Leong KW, Simonte V, Langer R. Synthesis of polyanhydrides: meltpolycondensation, dehydrochlorination, and dehydrative coupling. Macromolecules. 1987;20:705-712.
48. Sintzel MB, Heller J, Ng SY, Tabatabay C, Schwach-Abdellaoui K, Gurny R. In vitro drug release from self-catalyzed poly(ortho ester): case study of 5-fluorouracil. J Control Release. 1998;55:213-218.
49. Azevedo HS, Reis RL. Understanding the enzymatic degradation of biodegradable polymers and strategies to control their degradation rate. In: Rui L, Reis JSR, editors. Biodegradable Systems in Tissue Engineering and Regenerative Medicine. Boca Ratio, FL: CRC Press; 2004.
50. Edlund U, Albertsson AC. Degradable polymer microspheres for controlled drug delivery. In: Albertsson AA, Dusek AC, editors. Advances in Polymer Science. Berlin, Germany: Springer-Verlag; 2002.
51. Uhrich KE, Cannizzaro SM, Langer R., Shakesheff KM. Polymeric systems for controlled drug release. Chem Rev. 1999;99:3181-3198.
52. Hurrell S, Cameron RE. Polyglycolide: degradation and drug release. Part I: changes in morphology during degradation. J Mater Sci Mater Med. 2001;12:811-816.
53. Ward R, Anderson J, McVenes R, Stokes K. In vivo biostability of polysiloxane polyether polyurethanes: resistance to biologic oxidation and stress cracking. J Biomed Mater Res A. 2006;77:580-589.
54. Napoli A, Valentini M, Tirelli N, Muller M, Hubbell JA. Oxidationresponsive polymeric vesicles. Nat Mater. 2004;3:183-189.
55. Chen L, Li X, Li L, Guo S. Acetylated starch-based biodegradable materials with potential biomedical applications as drug delivery systems. Curr Appl Phys. 2007;7:e90-e93.
56. Wu Y, Yang W, Wang C, Hu J, Fu S. Chitosan nanoparticles as a novel delivery system for ammonium glycyrrhizinate. Int J Pharm. 2005;295:235-245.
57. Sarmento B, Ribeiro A, Veiga F, Sampaio P, Neufeld R, Ferreira D. Alginate/chitosan nanoparticles are effective for oral insulin delivery. Pharm Res. 2007;24:2198-2206.
58. Trickler WJ, Nagvekar AA, Dash AK. A novel nanoparticle formulation for sustained paclitaxel delivery. AAPSPharmSciTech. 2008;9:486-493.
59. Cheng J, Teply BA, Sherifi I, et al. Formulation of functionalized PLGA- PEG nanoparticles for in vivo targeted drug delivery. Biomaterials. 2007;28:869-876.
60. Du YZ, Cai LL, Li J, et al. Receptor-mediated gene delivery by folic acid-modified stearic acid-grafted chitosan micelles. Int J Nanomedicine. 2011;6:1559-1568.
61. Fanga Z, Bhandaria B. Encapsulation of polyphenols - a review. Trends Food Sci Technol. 2010;21:510-523.
62. Pinto Reis C, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine. 2006;2:8-21.
63. Duan J, Zhang Y, Chen W, et al. Cationic polybutyl cyanoacrylate nanoparticles for DNA delivery. J Biomed Biotechnol. 2009;2009: 149254.
64. Yang SC, Ge HX, Hu Y, Jiang XQ, Yang CZ. Formation of positively charged poly(butyl cyanoacrylate) nanoparticles stabilized with chitosan. Colloid Polym Sci. 2000;278:285-292.
65. Miyazaki S, Takahashi A, Kubo W, Bachynsky J, Loebenberg R. Poly n-butylcyanoacrylate (PNBCA) nanocapsules as a carrier for NSAIDs: in vitro release and in vivo skin penetration. J Pharm Pharm Sci. 2003;6:238-245.
66. Essawy H, Tauer K. Polyamide capsules via soft templating with oil drops-1. Morphological studies of the capsule wall. Colloid Polym Sci. 2010;288:317-331.
67. Crespy D, Landfester K. Miniemulsion polymerization as a versatile tool for the synthesis of functionalized polymers. Beilstein J Org Chem. 2010;6:1132-1148.
68. Hans ML, Lowman AM. Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater Sci. 2002;6:319-327.
69. Hong Y, Gao C, Shi Y, Shen J. Preparation of porous polylactide micro-spheres by emulsion-solvent evaporation based on solution induced phase separation. Polym Adv Technol. 2005;16:622-627.
70. Nagpal K, Kumar Singh SK, Mishra DN. Chitosan nanoparticles: a promising system in novel drug delivery. Chem Pharm Bull (Tokyo). 2010;58:1423-1430.
71. Yun Y, Cho YW, Park K. Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery. Adv Drug Deliv Rev. 2013;65:822-832.
72. Galindo-Rodriguez S, Allemann E, Fessi H, Doelker E. Physicochemical parameters associated with nanoparticle formation in the salting-out, emulsification-diffusion, and nanoprecipitation methods. Pharm Res. 2004;21:1428-1439.
73. Troy DB, editor. Remington: The Science and Practice of Pharmacy. 21st ed. Philadelphia, PA: Lippincott Williams & Wilkin; 2006.
74. Murakami H, Kobayashi M, Takeuchi H, Kawashima Y. Preparation of poly(DL-lactide-co-glycolide) nanoparticles by modified spontaneous emulsification solvent diffusion method. Int J Pharm. 1999;187: 143-152.
75. Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers (Basel). 2011;3:1377-1397.
76. Cansell F, Aymonier C. Design of functional nanostructured materials using supercritical fluids. J Supercrit Fluids. 2009;47:508-516.
77. Gupta VK, Karar PK, Ramesh S, Misra SP, Gupta A. Nanoparticle formulation for hydrophilic and hydrophobic drugs. Int J Res Pharm Sci. 2010;1:163-169.
78. Reverchon E, Adami R. Nanomaterials and supercritical fluids. J Supercrit Fluids. 2006;37:1-22.
79. Irfan M, Seiler M. Encapsulation using hyperbranched polymers: from research and technologies to emerging applications. Ind Eng Chem Res. 2010;49:1169-1196.
80. Gomez S, Gamazo C, San Roman B, Vauthier C, Ferrer M, Irachel JM. Development of a novel vaccine delivery system based on Gantrez nanoparticles. J Nanosci Nanotechnol. 2006;6:3283-3289.
81. Kowalczyk B, Lagzi I, Grzybowski BA. Nanoseparations: strategies for size and/or shape-selective purification of nanoparticles. Curr Opin Colloid Interface Sci. 2011;16:135-148.
82. Abdelwahed W, Degobert G, Stainmesse S, Fessi H. Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv Drug Deliv Rev. 2006;58:1688-1713.
83. Biro E, Nemeth AS, Sisak C, Feczko T, Gyenis J. Preparation of chitosan particles suitable for enzyme immobilization. J Biochem Biophys Methods. 2008;70:1240-1246.
84. Lemoine D, Francois C, Kedzierewicz F, Preat V, Hoffman M, Maincent P. Stability study of nanoparticles of poly(epsilon-caprolactone), poly(D,L-lactide) and poly(D,L-lactide-co-glycolide). Biomaterials. 1996;17:2191-2197.
85. Mima Y, Fukumoto S, Koyama H, et al. Enhancement of cell-based therapeutic angiogenesis using a novel type of injectable scaffolds of hydroxyapatite-polymer nanocomposite microspheres. PLoS One. 2012;7:e35199.
86. Venkatesan J, Kim SK. Chitosan composites for bone tissue engineering - an overview. Mar Drugs. 2010;8:2252-2266.
87. Jagur-Grodzinski J. Biomedical application of functional polymers. React Funct Polym. 1999;39:99-138.
88. Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H. Nanoparticles as drug delivery systems. Pharmacol Rep. 2012;64:1020-1037.
89. Vilar G, Tulla-Puche J, Albericio F. Polymers and drug delivery systems. Curr Drug Deliv. 2012;9:367-394.
90. Mei L, Zhang Y, Zheng Y, et al. A novel docetaxel-loaded poly (epsilon-caprolactone)/Pluronic F68 nanoparticle overcoming multidrug resistance for breast cancer treatment. Nanoscale Res Lett. 2009;4:1530-1539.
91. Mitra M, Misra R, Harilal A, Sahoo SK, Krishnakumar S. Enhanced in vitro antiproliferative effects of EpCAM antibody-functionalized paclitaxel-loaded PLGA nanoparticles in retinoblastoma cells. Mol Vis. 2011;17:2724-2737.
92. Foged C, Nielsen HM. Cell-penetrating peptides for drug delivery across membrane barriers. Expert Opin Drug Deliv. 2008;5:105-117.
93. Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL. A potential role of the curry spice curcumin in Alzheimer's disease. Curr Alzheimer Res. 2005;2:131-136.
94. Mathew A, Fukuda T, Nagaoka Y, et al. Curcumin loaded-PLGA nano-particles conjugated with Tet-1 peptide for potential use in Alzheimer's disease. PLoS One. 2012;7:e32616.
95. Songjiang Z, Lixiang W. Amyloid-beta associated with chitosan nano-carrier has favorable immunogenicity and permeates the BBB. AAPS PharmSciTech. 2009;10:900-905.
96. Azeem A, Talegaonkar S, Negi LM, Ahmad FJ, Khar RK, Iqbal Z. Oil based nanocarrier system for transdermal delivery of ropinirole: a mechanistic, pharmacokinetic and biochemical investigation. Int J Pharm. 2012;422:436-444.
97. Malvindi MA, Di Corato R, Curcio A, et al. Multiple functionalization of fluorescent nanoparticles for specific biolabeling and drug delivery of dopamine. Nanoscale. 2011;3:5110-5119.
98. Di Stefano A, Iannitelli A, Laserra S, Sozio P. Drug delivery strategies for Alzheimer's disease treatment. Expert Opin Drug Deliv. 2011;8: 581-603.
99. Wickline SA, Neubauer AM, Winter P, Caruthers S, Lanza G. Applications of nanotechnology to atherosclerosis, thrombosis, and vascular biology. Arterioscler Thromb Vasc Biol. 2006;26:435-441.
100. Mutsuga M, Narita Y, Yamawaki A, et al. Development of novel drug-eluting biodegradable nano-fiber for prevention of postoperative pulmonary venous obstruction. Interact Cardiovasc Thorac Surg. 2009;8:402-407.
101. Cho HH, Han DW, Matsumura K, Tsutsumi S, Hyon SH. The behavior of vascular smooth muscle cells and platelets onto epigallocatechin gallate-releasing poly(l-lactide-co-epsilon-caprolactone) as stentcoating materials. Biomaterials. 2008;29:884-893.
102. Bharali DJ, Mousa SA, Thanavala Y. Micro- and nanoparticle-based vaccines for hepatitis B. Adv Exp Med Biol. 2007;601:415-421.
103. Demento S, Steenblock ER, Fahmy TM. Biomimetic approaches to modulating the T cell immune response with nano- and micro-particles. Conf Proc IEEE Eng Med Biol Soc. 2009;2009: 1161-1166.
104. Vinogradov SV, Poluektova LY, Makarov E, Gerson T, Senanayake MT. Nano-NRTIs: efficient inhibitors of HIV type-1 in macrophages with a reduced mitochondrial toxicity. Antivir Chem Chemother. 2010;21:1-14.
105. Dwivedi V, Manickam C, Binjawadagi B, Joyappa D, Renukaradhya GJ. Biodegradable nanoparticle-entrapped vaccine induces cross-protective immune response against a virulent heterologous respiratory viral infection in pigs. PLoS One. 2012;7:e51794.
106. Brunel F, Veron L, David L, Domard A, Verrier B, Delair T. Self-assemblies on chitosan nanohydrogels. Macromol Biosci. 2010;10:424-432.
107. Liu H, Webster TJ. Ceramic/polymer nanocomposites with tunable drug delivery capability at specific disease sites. J Biomed Mater Res A. 2010;93:1180-1192.
108. Fox K, Tran PA, Tran N. Recent advances in research applications of nanophase hydroxyapatite. Chemphyschem. 2012;13:2495-2506.
109. Marrache S, Dhar S. Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics. Proc Natl Acad Sci U S A. 2012;109:16288-16293.
110. Sun D, Zhuang X, Xiang X, et al. A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol Ther. 2010;18:1606-1614.
111. Anand P, Nair HB, Sung B, et al. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol. 2010;79:330-338.
112. El-Shabouri MH. Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A. Int J Pharm. 2002;249: 101-108.
113. Banerjee SS, Aher N, Patil R, Khandare J. Poly(ethylene glycol)-prodrug conjugates: concept, design, and applications. J Drug Deliv. 2012;2012:103973.
114. Gref R, Domb A, Quellec P, et al. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Deliv Rev. 2012;16:215-233.
115. Zohuriaan-Mehr MJ. Advances in chitin and chitosan modification through graft copolymerization: a comprehensive review. Iran Polym J. 2005;14:235-265.
116. van Vlerken LE, Vyas TK, Amiji MM. Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery. Pharm Res. 2007;24:1405-1414.
117. Doherty GJ, McMahon HT. Mechanisms of endocytosis. Annu Rev Biochem. 2009;78:857-902.
118. Aderem A, Underhill DM. Mechanisms of phagocytosis in macrophages. Annu Rev Immunol. 1999;17:593-623.
119. Groves E, Dart AE, Covarelli V, Caron E. Molecular mechanisms of phagocytic uptake in mammalian cells. Cell Mol Life Sci. 2008;65: 1957-1976.
120. Gratton SE, Ropp PA, Pohlhaus PD, et al. The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci U S A. 2008;105:11613-11618.
121. Rejman J, Oberle V, Zuhorn IS, Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J. 2004;377:159-169.
122. Gandapu U, Chaitanya RK, Kishore G, Reddy RC, Kondapi AK. Curcumin-loaded apotransferrin nanoparticles provide efficient cellular uptake and effectively inhibit HIV-1 replication in vitro. PLoS One. 2011;6:e23388.
123. Ramanan V, Agrawal NJ, Liu J, Engles S, Toy R, Radhakrishnan R. Systems biology and physical biology of clathrin-mediated endocytosis. Integr Biol (Camb). 2011;3:803-815.
124. Smith PJ, Giroud M, Wiggins HL, et al. Cellular entry of nanoparticles via serum sensitive clathrin-mediated endocytosis, and plasma membrane permeabilization. Int J Nanomedicine. 2012;7:2045-2055.
125. Krajewska WM, Maslowska I. Caveolins: structure and function in signal transduction. Cell Mol Biol Lett. 2004;9:195-220.
126. Schnitzer JE, Oh P, Pinney E, Allard J. Filipin-sensitive caveolae-mediated transport in endothelium: reduced transcytosis, scavenger endocytosis, and capillary permeability of select macromolecules. J Cell Biol. 1994;127:1217-1232.
127. Hillaireau H, Couvreur P. Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol Life Sci. 2009;66:2873-2896.
128. Swanson JA, Watts C. Macropinocytosis. Trends Cell Biol. 1995;5: 424-428.
129. Harush-Frenkel O, Rozentur E, Benita S, Altschuler Y. Surface charge of nanoparticles determines their endocytic and transcytotic pathway in polarized MDCK cells. Biomacromolecules. 2008;9:435-443.
130. Damm EM, Pelkmans L, Kartenbeck J, Mezzacasa A, Kurzchalia T, Helenius A. Clathrin- and caveolin-1-independent endocytosis: entry of simian virus 40 into cells devoid of caveolae. J Cell Biol. 2005;168:477-488.
131. Mayor S, Pagano RE. Pathways of clathrin-independent endocytosis. Nat Rev Mol Cell Biol. 2007;8:603-612.
132. dos Santos T, Varela J, Lynch I, Salvati A, Dawson KA. Effects of transport inhibitors on the cellular uptake of carboxylated polystyrene nanoparticles in different cell lines. PLoS One. 2011;6:e24438.
133. des Rieux A, Fievez V, Garinot M, Schneider YJ, Préat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release. 2006;116:1-27.
134. Kamel AO, Awad GA, Geneidi AS, Mortada ND. Preparation of intravenous stealthy acyclovir nanoparticles with increased mean residence time. AAPS PharmSciTech. 2009;10:1427-1436.
135. Almeida AJ, Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev. 2007;59:478-490.
136. Innes NP, Ogden GR. A technique for the study of endocytosis in human oral epithelial cells. Arch Oral Biol. 1999;44:519-523.
137. Nabeshi H, Yoshikawa T, Akase T, et al. Effect of amorphous silica nanoparticles on in vitro RANKL-induced osteoclast differentiation in murine macrophages. Nanoscale Res Lett. 2011;6:464.
138. Eliaz RE, Nir S, Marty C, Szoka FC Jr. Determination and modeling of kinetics of cancer cell killing by doxorubicin and doxorubicin encapsulated in targeted liposomes. Cancer Res. 2004;64:711-718.
139. Chen M, Gao S, Dong M, et al. Chitosan/siRNA nanoparticles encapsulated in PLGA nanofibers for siRNA delivery. ACS Nano. 2012;6:4835-4844.
140. Song J, Kahveci D, Chen M, et al. Enhanced catalytic activity of lipase encapsulated in PCL nanofibers. Langmuir. 2012;28:6157-6162.
141. Zhang J, Chen XG, Liu CS, Park HJ. Investigation of polymeric amphiphilic nanoparticles as antitumor drug carriers. J Mater Sci Mater Med. 2009;20:991-999.
142. Shi X, Thomas TP, Myc LA, Kotlyar A, Baker JR Jr. Synthesis, characterization, and intracellular uptake of carboxyl-terminated poly(amidoamine) dendrimer-stabilized iron oxide nanoparticles. Phys Chem Chem Phys. 2007;9:5712-5720.
143. Wang JJ, Zeng ZW, Xiao RZ, et al. Recent advances of chitosan nano-particles as drug carriers. Int J Nanomedicine. 2011;6:765-774.
144. Georgieva JV, Kalicharan D, Couraud PO, et al. Surface characteristics of nanoparticles determine their intracellular fate in and processing by human blood-brain barrier endothelial cells in vitro. Mol Ther. 2011;19:318-325.
145. Baoum A, Dhillon N, Buch S, Berkland C. Cationic surface modification of PLG nanoparticles offers sustained gene delivery to pulmonary epithelial cells. J Pharm Sci. 2010;99:2413-2422.
146. de Salamanca AE, Diebold Y, Calonge M, et al. Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and in vivo tolerance. Invest Ophthalmol Vis Sci. 2006;47:1416-1425.
147. Roy S, Pal K, Anis A, Pramanik K, Prabhakar B. Polymers in mucoadhesive drug delivery system: a brief note. Des Monomers Polym. 2009;12:483-495.
148. Talaei F, Azizi E, Dinarvand R, Atyabi F. Thiolated chitosan nano-particles as a delivery system for antisense therapy: evaluation against EGFR in T47D breast cancer cells. Int J Nanomedicine. 2011;6:1963-1975.
149. Shuvaev VV, Ilies MA, Simone E, et al. Endothelial targeting of antibody-decorated polymeric filomicelles. ACS Nano. 2011;5: 6991-6999.
150. Kim J, Dadsetan M, Ameenuddin S, Windebank AJ, Yaszemski MJ, Lu L. In vivo biodegradation and biocompatibility of PEG/sebacic acid-based hydrogels using a cage implant system. J Biomed Mater Res A. 2010;95:191-197.
151. Nicolete R, dos Santos DF, Faccioli LH. The uptake of PLGA micro or nanoparticles by macrophages provokes distinct in vitro inflammatory response. Int Immunopharmacol. 2011;11:1557-1563.
152. Wang ZG, Hsiao BS, Zong XH, et al. Morphological development in absorbable poly(glycolide), poly(glycolide-co-lactide) and poly(glycolide-co-caprolactone) copolymers during isothermal crystallization. Polymer. 2000;4:621-628.
153. Niederman R, Zhang J, Kashket S. Short-chain carboxylic-acid-stimulated, PMN-mediated gingival inflammation. Crit Rev Oral Biol Med. 1997;8:269-290.
154. Mitra S, Gaur U, Ghosh PC, Maitra AN. Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J Control Release. 2001;74:317-323.
155. Loh JW, Yeoh G, Saunders M, Lim LY. Uptake and cytotoxicity of chitosan nanoparticles in human liver cells. Toxicol Appl Pharmacol. 2010;249:148-157.
156. Moghimi SM, Symonds P, Murray JC, Hunter AC, Debska G, Szewczyk A. A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy. Mol Ther. 2005;11: 990-995.
157. Gupta KC, Kumar P, Swami A, Pathak A, Inventors. Novel crosslinked pei nanoparticle based transfection agents for delivery of biomolecules. United States Patent US20100029750 A1. February 4, 2010.
158. Goyal R, Tripathi SK, Tyagi S, et al. In vitro and in vivo evaluation of linear polyethylenimine nanoparticles. J Biomed Nanotechnol. 2011;7:52-53.
159. Tag Ko Y, Kale A, Hartner W, Papahadjopoulos-Sternberg B, Torchilina V. Self-assembling micelle-like nanoparticles based on phospholipid-polyethyleneimine conjugates for systemic gene delivery. J Control Release. 2009;133:132-138.
160. Xiao J, Duan X, Yin Q, Chen L, Zhang Z, Li Y. Low molecular weight polyethylenimine-graft-Tween 85 for effective gene delivery: synthesis and in vitro characteristics. Bioconjug Chem. 2012;23:222-231.
161. Fernandez-Carballido A, Pastoriza P, Barcia E, Montejo C, Negro S. PLGA/PEG-derivative polymeric matrix for drug delivery system applications: characterization and cell viability studies. Int J Pharm. 2008;352:50-57.
162. Liu J, Jiang Z, Zhang S, Saltzman WM. Poly(omega-pentadecalactone-co-butylene-co-succinate) nanoparticles as biodegradable carriers for camptothecin delivery. Biomaterials. 2009;30:5707-5719.
163. Deschamps AA, Grijpma DW, Feijen J. Poly(ethylene oxide)/ poly(butylene terephthalate) segmented block copolymers: the effect of copolymer composition on physical properties and degradation behavior. Polymer. 2001;42:9335-9345.
164. Gibas I, Janik H. Review: synthetic polymer hydrogels for biomedical applications. Chem Chem Technol. 2010;4:297-304.
165. Batheja P, Sheihet L, Kohn J, Singer AJ, Michniak-Kohn B. Topical drug delivery by a polymeric nanosphere gel: formulation optimization and in vitro and in vivo skin distribution studies. J Control Release. 2011;149:159-167.
166. Errico C, Bartoli C, Chiellini F, Chiellini E. Poly(hydroxyalkanoates)- based polymeric nanoparticles for drug delivery. J Biomed Biotechnol. 2009;2009:571702.
167. Moebus K, Siepmann J, Bodmeier R. Alginate-poloxamer microparticles for controlled drug delivery to mucosal tissue. Eur J Pharm Biopharm. 2009;72:42-53.
168. Li X, Yang Z, Yang K, et al. Self-assembled polymeric micellar nano-particles as nanocarriers for poorly soluble anticancer drug ethaselen. Nanoscale Res Lett. 2009;4:1502-1511.
169. Rai B, Teoh SH, Hutmacher DW, Cao T, Ho KH. Novel PCL-based honeycomb scaffolds as drug delivery systems for rhBMP-2. Biomaterials. 2005;26:3739-3748.
170. Helle J, Barr J, Ng SY, et al. Development and applications of injectable poly(ortho esters) for pain control and periodontal treatment. Biomaterials. 2002;23:4397-4404.
171. Gunatillake PA, Adhikari R. Biodegradable synthetic polymers for tissue engineering. Eur Cell Mater. 2003;5:1-16.
172. Bernkop-Schnurch A, Dunnhaupt S. Chitosan-based drug delivery systems. Eur J Pharm Biopharm. 2012;81:463-469.
173. Thanou M, Verhoef JC, Junginger HE. Oral drug absorption enhancement by chitosan and its derivatives. Adv Drug Deliv Rev. 2001;52:117-126.
174. Bhattacharjee S, Ershov D, Fytianos K, et al. Cytotoxicity and cellular uptake of tri-block copolymer nanoparticles with different size and surface characteristics. Part Fibre Toxicol. 2012;9:11.
175. Mihai R, Florescu IP, Coroiu V, Oancea A, Lungu M. In vitro biocompatibility testing of some synthetic polymers used for the achievement of nervous conduits. J Med Life. 2011;4:250-255.
176. Bertram JP, Jay SM, Hynes SR, Robinson R, Criscione JM, Lavik EB. Functionalized poly(lactic-co-glycolic acid) enhances drug delivery and provides chemical moieties for surface engineering while preserving biocompatibility. Acta Biomater. 2009;5:2860-2871.
177. Hu YL, Qi W, Han F, Shao JZ, Gao JQ. Toxicity evaluation of biodegradable chitosan nanoparticles using a zebrafish embryo model. Int J Nanomedicine. 2011;6:3351-3359.
178. da Silva LC, Garcia T, Mori M, et al. Preparation and characterization of polysaccharide-based nanoparticles with anticoagulant activity. Int J Nanomedicine. 2012;7:2975-2986.